Cargando…

Taking stock of cost-effectiveness analysis of healthcare in China

INTRODUCTION: Cost-effectiveness analysis (CEA) is playing an increasingly important role in informing healthcare decision-making in China. This study aims to review the published literature on CEA in mainland China and describe its characteristics and evolution. We provide recommendations on the fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Thomas, Liu, Gordon G, Kim, David D, Neumann, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528776/
https://www.ncbi.nlm.nih.gov/pubmed/31179038
http://dx.doi.org/10.1136/bmjgh-2019-001418
_version_ 1783420302128054272
author Butt, Thomas
Liu, Gordon G
Kim, David D
Neumann, Peter J
author_facet Butt, Thomas
Liu, Gordon G
Kim, David D
Neumann, Peter J
author_sort Butt, Thomas
collection PubMed
description INTRODUCTION: Cost-effectiveness analysis (CEA) is playing an increasingly important role in informing healthcare decision-making in China. This study aims to review the published literature on CEA in mainland China and describe its characteristics and evolution. We provide recommendations on the future direction of CEA as a methodology and as a tool to support healthcare decision-making in China. METHODS: English-language cost-per-quality-adjusted life-year (QALY) and cost-per-disability-adjusted life-year (DALY) publications relating to mainland China were reviewed using the Tufts Medical Center Cost-Effectiveness Analysis Registry and Global Health Cost-Effectiveness Analysis Registry through 2017. Study features were summarised using descriptive statistics. Changes in study methodology over time were analysed by trend test, and study characteristics influencing the incremental cost-effectiveness ratio (ICER) of cost-per-QALY studies were investigated using logistic regression. RESULTS: 170 studies were identified reporting CEA for mainland China (cost/QALY=125, cost/DALY=45) since 1998. The number and quality of studies has increased over the past two decades, with significantly more cost-per-QALY studies compared with cost-per-DALY studies (p<0.0001) and more studies with authors affiliated with Chinese institutions (p=0.0002). The average quality score was 5.04 out of 7 for cost-per-QALY and 4.70 for cost-per-DALY studies based on Registry reviewers’ subjective assessment of overall quality (methods, assumptions and reporting practices). The median ICER reported for interventions for oncology patients was higher (US$26 694 per QALY) than the median ICER reported for all interventions (US$11 503 per QALY). Oncology interventions were associated with the likelihood of reporting higher ICERs than the median ICER (p=0.003). CONCLUSION: The number of English-language published CEA studies relating to China has grown rapidly over the past 20 years. In terms of quality, the China studies compare favourably with international studies, although they remain a small proportion of studies globally.
format Online
Article
Text
id pubmed-6528776
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65287762019-06-07 Taking stock of cost-effectiveness analysis of healthcare in China Butt, Thomas Liu, Gordon G Kim, David D Neumann, Peter J BMJ Glob Health Research INTRODUCTION: Cost-effectiveness analysis (CEA) is playing an increasingly important role in informing healthcare decision-making in China. This study aims to review the published literature on CEA in mainland China and describe its characteristics and evolution. We provide recommendations on the future direction of CEA as a methodology and as a tool to support healthcare decision-making in China. METHODS: English-language cost-per-quality-adjusted life-year (QALY) and cost-per-disability-adjusted life-year (DALY) publications relating to mainland China were reviewed using the Tufts Medical Center Cost-Effectiveness Analysis Registry and Global Health Cost-Effectiveness Analysis Registry through 2017. Study features were summarised using descriptive statistics. Changes in study methodology over time were analysed by trend test, and study characteristics influencing the incremental cost-effectiveness ratio (ICER) of cost-per-QALY studies were investigated using logistic regression. RESULTS: 170 studies were identified reporting CEA for mainland China (cost/QALY=125, cost/DALY=45) since 1998. The number and quality of studies has increased over the past two decades, with significantly more cost-per-QALY studies compared with cost-per-DALY studies (p<0.0001) and more studies with authors affiliated with Chinese institutions (p=0.0002). The average quality score was 5.04 out of 7 for cost-per-QALY and 4.70 for cost-per-DALY studies based on Registry reviewers’ subjective assessment of overall quality (methods, assumptions and reporting practices). The median ICER reported for interventions for oncology patients was higher (US$26 694 per QALY) than the median ICER reported for all interventions (US$11 503 per QALY). Oncology interventions were associated with the likelihood of reporting higher ICERs than the median ICER (p=0.003). CONCLUSION: The number of English-language published CEA studies relating to China has grown rapidly over the past 20 years. In terms of quality, the China studies compare favourably with international studies, although they remain a small proportion of studies globally. BMJ Publishing Group 2019-05-14 /pmc/articles/PMC6528776/ /pubmed/31179038 http://dx.doi.org/10.1136/bmjgh-2019-001418 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Butt, Thomas
Liu, Gordon G
Kim, David D
Neumann, Peter J
Taking stock of cost-effectiveness analysis of healthcare in China
title Taking stock of cost-effectiveness analysis of healthcare in China
title_full Taking stock of cost-effectiveness analysis of healthcare in China
title_fullStr Taking stock of cost-effectiveness analysis of healthcare in China
title_full_unstemmed Taking stock of cost-effectiveness analysis of healthcare in China
title_short Taking stock of cost-effectiveness analysis of healthcare in China
title_sort taking stock of cost-effectiveness analysis of healthcare in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528776/
https://www.ncbi.nlm.nih.gov/pubmed/31179038
http://dx.doi.org/10.1136/bmjgh-2019-001418
work_keys_str_mv AT buttthomas takingstockofcosteffectivenessanalysisofhealthcareinchina
AT liugordong takingstockofcosteffectivenessanalysisofhealthcareinchina
AT kimdavidd takingstockofcosteffectivenessanalysisofhealthcareinchina
AT neumannpeterj takingstockofcosteffectivenessanalysisofhealthcareinchina